Through her work in the graduate program, Holmes eventually came up with the idea that would become Theranos' selling point: creating a small device that can run multiple tests with a simple drop of blood. She quickly raises $6 million (no biggie) and has her professor come on as Theranos' first board member.
Things take off relatively fast both with the company as a whole and within the creative department, which is responsible for coming up with the working device (given Holmes' lack of knowledge on the subject). After all, it's great to start a company specializing in medical engineering if you don't understand any of the processes, right?
After tons of test runs and instances of blood-leaking out of the machine (which was surprisingly chilling to watch), the team is finally able to get the device to work.
They literally only get the device to work once and then decide to bring it to Pfizer and then to a clinical trial with real cancer patients, fully knowing that the devices aren't functional. In just three episodes, things are already chaotic with Holmes and Theranos as she's essentially touting widespread lies to receive more funding.
Regardless of the series being more of a time commitment given that the episodes are about an hour-long, each second is pure gold; not a moment is wasted as the bits of the past that are shown of Holmes are absolutely necessary for getting a better sense of her as an all-encompassing person. We see slices of the younger Holmes that are sprinkled in throughout later episodes, including her odd and offbeat dancing, which continues to appear even in her days at Theranos.